02256 Overview

US Economic Outlook: The US economy is projected to experience moderate growth next year, supported by the Fed's rate cuts and AI investments, while maintaining a bullish stance on US stocks despite short-term risks.

Hong Kong Stock Market Forecast: Hong Kong stocks are expected to transition from valuation recovery to earnings growth, with liquidity remaining favorable despite challenges in China's economy.

Top Stock Recommendations: CMSI's top stock picks for Q1 2026 include major companies like Alphabet, Meta, Netflix, Tencent, and Alibaba, among others.

Short Selling Data: The report includes detailed short selling data for various stocks, highlighting significant short selling ratios for companies like Geely Auto and BYD Company.

Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.

Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.

Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.

Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.

Market Growth: Chinese biotech stocks in Hong Kong have surged by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% growth, indicating a shift in market perception of domestic pharmaceutical innovation.

Investment Outlook: Morgan Stanley predicts that the US Federal Reserve's rate cuts will boost risk appetite, directing funds towards growth sectors like Chinese biotech, while emphasizing that stock performance will still depend on fundamentals such as commercialization and R&D progress.